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Abstract
To understand the molecular mechanisms of metastasis and prognosis of colorectal cancer
(CRC), we isolated single cell-derived progenies (SCPs) from SW480 cells in vitro and
compared their metastatic potential in an orthotopic CRC tumour model in vivo. Two groups
of SCPs with the capability of high and low metastasis, respectively, were obtained. By
analysing the gene expression profiles of high (SCP51), low (SCP58) metastatic SCPs, and
their parental cell line (SW480/EGFP), we demonstrated that 143 genes were differentially
expressed either between SCP51 and SCP58 or between SCP58 and SW480/EGFP. Gene-
annotation enrichment analysis of DAVID revealed 80 genes in the top ten clusters of the
analysis (gene enrichment score >1). Of the 80-gene set, 32 genes are potentially involved in
metastasis, as revealed by Geneclip. Five putative metastatic genes (LYN, SDCBP, MAP4K4,
DKK1, and MID1 ) were selected for further validations. Immunohistochemical analysis
in a cohort of 181 CRC clinical samples showed that the individual expression of LYN,
MAP4K4, and MID1, as well as the five-gene signature, was closely correlated with lymph
node metastasis in CRC patients. More importantly, the individual expression of LYN,
MAP4K4, SDCBP, and MID1, as well as the five-gene signature, was significantly correlated
with overall survival in CRC patients. Thus, our five-gene signature may be able to predict
metastasis and survival of CRC in the clinic, and opens new perspectives on the biology of
CRC.
Copyright  2009 Pathological Society of Great Britain and Ireland. Published by John
Wiley & Sons, Ltd.
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Introduction
Metastasis is the main cause leading to death of col-
orectal cancer (CRC) patients. However, the molecu-
lar mechanisms of metastasis of CRC remain largely
unknown. The discovery of novel biomarkers has rele-
vance for the early diagnosis, prevention, and possible
target therapy of CRC patients, as well as providing
new biological insights. Microarray profiling has been
shown to be a valuable technique to uncover biomark-
ers or prognosis factors for patients with different
types of cancer [1–5]. A gene expression signature,
defined as the expression pattern of a particular set
of genes, has been widely used in identification of
the specific cancer type or subtype, prediction of the
outcome of patients, and selection of the appropriate
therapeutic treatment [6–8].
Two common strategies based on the gene expres-
sion profiling technique have been used to identify
novel biomarkers associated with many characteristics
of cancer. Profiling of human tissue can distinguish the
gene expression between normal and tumour tissues
from patients. This approach usually results in large
numbers of such genes and only a small proportion of
these genes may be clinically useful. The second strat-
egy is based on the notion that only a few cells from
a heterogeneous population have metastatic capabil-
ity. Therefore, metastatic variants can be isolated from
the primary bulk of the tumour. In vivo selection has
been used to discern genetic determinants of metas-
tasis. Using this approach, Massague and co-workers
have reported gene signatures mediating breast can-
cer metastasis to bone [9], lung [10], and brain [11].
The molecular signatures derived from mouse tumour
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models could successfully predict the progression and
prognosis of breast cancer.
In this study, we isolated single cell-derived proge-
nies (SCPs) with different metastatic potentials from
the SW480 cell line in vitro and compared their gene
expression profiles in vivo. We identified a 32-gene
set as the candidate genes associated with metastasis
of CRC by cross-comparing, functional analysis and
gene annotation, and text mining. In a cohort of 181
CRC clinical samples, we validated the expression of a
five-gene signature and each of the five genes in CRC.
We found that the five-gene signature may be able to
predict metastasis and patient survival of CRC.
Materials and methods
Cell culture
The human CRC cell line SW480 was obtained from
the Cell Bank at the Chinese Academy of Sciences
(Shanghai, China). SW480/EGFP was established
from SW480 by transfection of pEGFP-N1 plasmid.
Tumour cells were cultured in RPMI 1640 medium
(Gibco, Grand Island, NY, USA) supplemented with
10% fetal bovine serum (Hyclone, Logan, UT, USA)
and 100 U/ml penicillin/streptomycin (Gibco), and
incubated in a humidified chamber with 5% CO2 at
37 ◦C. SW480/EGFP cells were diluted in medium at
2–10 cells/ml. 100 µl of the dilution was added to
each well of a 96-well plate. Wells containing a single
clone derived from one cell were identified under a
microscope (Figure 1A). Clones were then expanded
in 10-cm tissue culture plates.
Cell proliferation assay
Tumour cells were prepared at a concentration of
1 × 103 cells/ml. Aliquots (200 µl) of the cells were
dispensed in triplicate into 96-well plates. After
indicated days, 20 µl of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) (5 mg/ml;
Promega) was added to each well. Four hours later,
the supernatant was removed and 150 µl of dimethyl
sulphoxide (Sigma, St Louis, MO, USA) was added.
After 15-min incubation, the absorbance value (OD)
was measured at 570 nm in a micro-plate reader. Four
independent experiments were performed.
Tumour xenografts
Xenograft tumours were generated by subcutaneous
injection of 5 × 106 cells on the flanks of nude
mice. Orthotopic implantation of the tumour fragment
obtained from the subcutaneous tumour to the caecum
was performed (Supporting information, Supplemental
experimental procedures) as described previously [12].
To observe tumour growth, fluorescence emitted by
tumour cells was imaged by a whole-body green flu-
orescence protein (GFP) imaging system (Lighttools,
Encinitas, CA, USA). Images were then analysed to
calculate the tumour area and tumour growth using
IPP5.0 software (Cybermetics Co, Silver Spring, MD,
USA). To dissect tumour metastasis, various organs
were collected from the tumour-bearing mice. The
samples was fixed in 10% neutral buffered formalin,
embedded in paraffin, and stained with haematoxylin
and eosin.
Microarray analysis
Nine samples, three from parental SW480/EGFP, three
from SCP51 with high metastatic potential, and three
from SCP58 with low metastatic potential, were col-
lected. Total RNA was extracted from the samples
using a Qiagen RNeasy kit (Qiagen, Chatsworth, CA,
USA). The Affymetrix Human Genome U133 Plus 2.0
Array GeneChips (Affymetrix, Santa Clara, CA, USA)
were used for microarray analysis. Hybridization and
scanning of the genechips were performed by the
CapitalBio Biotechnology Company (Beijing, China)
according to the standard Affymetrix protocol (Sup-
porting information, Supplementary experimental pro-
cedures). The data have been deposited in the public
Gene Expression Omnibus repository (Accession num-
ber GSE16934). Significance analysis of microarrays
(SAM) was performed to identify the genes expressed
differentially between SCP51 and SCP58, or between
SCP58 and SW480/EGFP. Common differential genes
were obtained by cross-comparing the two data sets.
Functional analysis and gene annotation
The Database for Annotation, Visualization, and
Integrated Discovery (DAVID) was used to dis-
cover enriched function-related gene groups by gene-
annotation enrichment analysis (http://david.abcc.
ncifcrf.gov/). The genes in the top ten clusters
(gene enrichment score >1) from the gene-annotation
enrichment analysis were selected. Geneclip [13], a
software program for clustering gene lists by liter-
ature profiling and constructing gene co-occurrence
networks, was used to acquire a primary profile of
known genes related to metastasis in colorectal cancer,
melanoma, and other cancers.
Reverse transcription-polymerase chain reaction
(RT-PCR)
RT-PCR was performed to measure the expression
of LYN, SDCBP, MAP4K4, MID1, and DKK1 at
the mRNA level in fresh colorectal tumour samples.
Total RNA was extracted from the tumour using Trizol
reagent (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s instructions. RNA was treated with
DNase and used for cDNA synthesis with random
hexamers. The primers used for amplifying LYN,
SDCBP, MAP4K4, MID1, and DKK1 have been
described in the Supporting information, Supplemental
experimental procedures.
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Western blot analysis
Mouse monoclonal antibodies to DKK1, MAP4K4,
and MID1, and rabbit polyclonal antibodies to LYN
and SDCBP were purchased from Abcam (Cambridge,
UK). Procedural details of western blotting have been
described in the Supporting information, Supplemental
experimental procedures.
Immunohistochemical staining and scoring
Formalin-fixed, paraffin-embedded colorectal tumour
samples obtained from patients at the Nanfang Hos-
pital of Southern Medical University (Guangzhou,
China) were used in our clinicopathological investi-
gation. Individual consent on use of the clinical sam-
ple for research purposes was obtained from each
patient and approved by the Ethical Committee of
Southern Medical University. Histological classifica-
tion and clinicopathological staging of the tumours
were performed according to the Japanese General
Rules for Clinical and Pathological Studies on Can-
cer of the Colon, Rectum, and Anus, along with
the International Union Against Cancer Classification.
Immunohistochemical staining was performed using a
Dako EnVision System (Dako, Carpentaria, CA, USA)
following the protocol recommended by the manu-
facturer to study the expression of LYN, SDCBP,
MAP4K4, MID1, and DKK1 in 181 clinical samples.
Mouse anti-MAP4K4 monoclonal antibody (1 : 100;
Sigma-Aldrich, St Louis, USA), rabbit anti-human
MID1 polyclonal antibody (1 : 50; Abnova, Taiwan),
rabbit anti-human SDCBP (1 : 25), LYN (1 : 50), and
DKK1 (1 : 10) polyclonal antibodies (Abcam, Cam-
bridge, UK) were used in the study. The stained
tumours were reviewed and scored separately by two
pathologists blinded to the patients’ clinical character-
istics. Scoring of the tumour staining was performed as
described previously [14,15]. Briefly, the intensity of
staining was scored as negative (0), weak (1), medium
(2), or strong (3). The extent of staining, defined as
the percentage of positive staining areas in relation
to the whole tumour section, was scored as 0 (0%), 1
(1–25%), 2 (26–50%), 3 (51–75%), or 4 (76–100%).
An overall expression score, ranging from 0 to 12, was
calculated by multiplying the score of intensity and
that of extent.
For statistical analysis, a final score number ≥4 was
considered high expression of the protein of interest.
The score for the five-gene signature was calculated
from the value of each gene in the signature. Since up-
regulation of LYN, SDCBP, and MAP4K4 contributed
to the progression of CRC, high expression was scored
as 1, while low expression was scored as 0 for these
genes. However, since down-regulation of MID1 and
DKK1 was also associated with CRC progression, for
these genes low expression was scored as 1, while high
expression was scored as 0. The sum of the scores for
the five proteins was regarded as the score of the five-
gene signature. For statistical analysis, a final score
≥3 was considered to be positive expression of the
five-gene signature.
Statistical analysis
Statistical analyses were performed using the SPSS
software program (version 12.0; SPSS Inc, Chicago,
IL, USA) and the results were confirmed by statisti-
cians in the Department of Health Statistics, Southern
Medical University. The chi-square test was used to
assess differences in metastasis and peritoneal dis-
semination of tumour cells. The Mann–Whitney U -
test was used to analyse the relationship between the
expression of LYN, SDCBP, MAP4K4, MID1, DKK1
or the five-gene signature and clinicopathological char-
acteristics of the patients. Survival curves for the
patients with different expression of LYN, SDCBP,
MAP4K4, MID1, and DKK1 were plotted using the
Kaplan–Meier method and compared using the log-
rank test. The significance of various survival-related
variables was assessed using the Cox proportional haz-
ards model in a multivariate analysis. In vitro prolifer-
ation assay, in vivo tumour growth assay, cell motility
assay, and metastatic potentials of SCPs were tested
using ANOVA. Statistical significance was concluded
where p ≤ 0.05 and is denoted in the figures by an
asterisk.
Results
Isolation and metastatic characterization of single
cell-derived progenies
A total of 59 SCPs were isolated from SW480/EGFP.
Subcutaneous implantation of SCPs on flanks of nude
mice showed that 29 SCPs (SCP3, SCP5, SCP8, SCP9,
SCP10, SCP11, SCP12, SCP15, SCP20, SCP21,
SCP23, SCP27, SCP28, SCP30, SCP31, SCP32,
SCP33, SCP34, SCP35, SCP36, SCP37, SCP38,
SCP43, SCP44, SCP50, SCP51, SCP55, SCP57, and
SCP58) exhibit the capacity of tumourigenicity to pro-
duce a visible tumour (Figures 1B and 1C). SCPs that
formed a subcutaneous tumour in ≥3 out of seven
mice were selected for further study. The ability of an
individual SCP to grow as a tumour under the skin
of nude mice was shown to be significantly differ-
ent (F = 33.446, p = 0.000) (Supporting information,
Supplementary Table 1).
To mimic human colorectal cancer, seven SCPs
were orthotopically implanted into the caecum indi-
vidually. Dissection of the metastasis in several com-
monly metastasized sites including the peritoneal cav-
ity, lymph node, and liver demonstrated that SCPs
could be categorized into two groups based on their
metastatic potential. SW480/EGFP, SCP12, SCP21,
and SCP51 exhibited high metastatic potential, while
SCP11, SCP28, and SCP58 had low metastatic poten-
tial (Figure 2A). To confirm the metastatic charac-
teristics, orthotopic xenografts were performed again
for SCP21, SCP51, SCP28, and SCP58. As shown in
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Figure 1. Single cell-derived progenies (SCPs) were isolated from SW480/EGFP. (A) In vitro growth and clonal formation of SCP1
observed under a fluorescent microscope. (B) Whole-body optical images of the SCP3 tumour that grew subcutaneously on
the flanks of nude mice. (C) Tumour samples of SCP3, SCP20, SCP10, SCP28, SCP58, SCP11, SCP9, SCP51, and SW480/EGFP
collected after subcutaneous growth on the flanks of nude mice for 5 weeks
Figure 2B, SCP21 and SCP51 were the high metastatic
variants, whereas SCP28 and SCP58 were the low
metastatic variants. The enhanced metastasis of SCP51
in lymph node and liver is demonstrated in Figures 2C
and 2D.
In vitro proliferation, in vivo tumour growth, and
migration of SCP51, SCP58, and SW480/EGFP
Next, we assessed the proliferation and migration
capabilities of the SCPs. As shown in Figures 3A
and 3B, both in vitro and in vivo SCP51 grew faster
than SW480/EGFP, while SCP58 proliferated more
slowly than SW480/EGFP. In vitro wound-healing
migration assay showed that after 72 h, SCP51 cells
filled in about 80% of the scratched area, whereas
SCP58 cells filled in only about 20% of the scratched
area (Figure 3C). Cell cycle analysis of SCP51,
SCP58, and SW480/EGFP cells by flow cytometry
demonstrated that the cell number of the G1 phase
and the proliferative index (the percentage of S + G2
nuclei in the DNA histogram) of SCP51 were signifi-
cantly increased compared with those of SW480/EGFP
or SCP58 (Supporting information, Supplementary
Table 2).
Identification of 32 candidate genes
with metastatic potential
To investigate the molecular signature underlining the
enhanced metastasis, we then carried out microar-
ray analysis using Affymetrix human genechips. Sev-
eral approaches were used to identify the candi-
date genes mediating CRC metastasis (Figure 4A).
First, we screened the genes expressed differentially
between SCP51 and SCP58 (SCP51 versus SCP58),
or between SCP58 and SW480/EGFP (SW480/EGFP
versus SCP58), using SAM with a false-discovery
rate of 4%. A total of 439 genes (derived from
612 probes), with 229 up-regulated and 210 down-
regulated, were found to be differentially expressed
between SCP51 and SCP58 (Supporting informa-
tion, Supplementary Table 3). Similarly, a total of
313 genes (from 359 probes), with 153 up-regulated
and 160 down-regulated, were differentially expressed
between SW480/EGFP and SCP58 (Supporting infor-
mation, Supplementary Table 4). Next, we cross-
compared the 439 genes expressed differentially
between SCP51 and SCP58 with the 313 genes
expressed differentially between SCP58 and SW480/
EGFP. 143 genes were found to have metasta-
tic potential (Figure 4B and Supporting information,
J Pathol 2010; 220: 475–489 DOI: 10.1002/path
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Figure 2. Spontaneous metastasis of SCPs in lymph node and liver, and peritoneal dissemination in orthotopic xenograft models.
(A) Spontaneous metastasis and peritoneal dissemination of SCP12, SCP21, SCP51, SCP11, SCP28, SCP58, and SW480/EGFP.
(B) Spontaneous metastasis and peritoneal dissemination of SCP51, SCP21, SCP28, and SCP58. (C) Whole-body optical images
of lymphatic metastasis of SCP51 in the orthotopic mouse model. Lymphatic metastasis was confirmed by histological analyses.
(D) Whole-body optical images of liver metastasis of SCP51 in the orthotopic mouse model. Liver metastasis was confirmed by
histological examinations
Supplementary Table 5). We then further analysed
these genes using the gene-annotation enrichment
analysis of DAVID (gene enrichment score >1) and
found that 80 genes were enriched in the top ten clus-
ters (Supporting information, Supplementary Tables 6
and 7). Finally, we analysed the potential functions
of these 80 genes by using Geneclip, a text-mining
program.
Thirty-two genes were found to be closely asso-
ciated with metastasis. These genes are known to
be involved in several important pathways, such
as transcription regulation (SMARCA2 , FOXO1A,
HOXB8 , etc), development (SEMA3A, MSX1 ,
COL6A3 , etc), cell motility (MARCKS , JAG1 ,
THBS1 , etc), and signal transduction (LYN , VDR,
SAV1 , etc) (Supporting information, Supplementary
Table 8). As shown in Figure 4C, SCP51, SCP58,
and SW480/EGFP were clearly clustered into three
subgroups based on their metastatic potential using
the 32-gene set. The literature profiling and con-
structing gene co-occurrence networks of the 32-
gene set by the Geneclip analysis suggested that
these 32 genes had important roles in metasta-
sis (Figure 4D). A primary co-occurrence network
between the 32-gene set and metastasis, colorectal
cancer, melanoma, and other cancers further high-
lighted the potential of these genes in tumour metas-
tasis (Figure 4E).
Validation of the expression of LYN, SDCBP,
MAP4K4, DKK1, and MID1 in the primary
tumours
We selected LYN, SDCBP, MAP4K4, DKK1, and
MID1 from the 32-gene set for further investiga-
tions since their roles in CRC were unclear. Both
J Pathol 2010; 220: 475–489 DOI: 10.1002/path
Copyright  2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
A five-gene signature as a potential predictor of metastasis and survival in CRC 481
Figure 3. In vitro proliferation, in vivo tumour growth, and migration of SCP51, SCP58, and SW480/EGFP. (A) In vitro growth
of SCP51 and SCP58 cells and SW480/EGFP. The values represent the absorbance value (OD) detected by MTT assay.
(B) Subcutaneous growth of the tumours of SCP58, SCP51, and SW480/EGFP on the flanks of nude mice. Each value represents
the mean ± SD of the tumour volume. (C) Cell migration of SCP51, SCP58, and SW480/EGFP for 72 h in a scratch wound-healing
assay
RT-PCR and western blotting were used to validate
their expression in fresh CRC samples. As shown
in Figure 5, compared with that of the paired nor-
mal tissues, the expression of LYN and SDCBP was
increased in most of the tumours at both mRNA and
protein levels. In contrast, the expression of DKK1
was decreased in most of the tumours. For MID1,
the expression of mRNA and protein of 75 kD, but
not 34 kD, was decreased in most of the tumours.
MID1 is known to be associated with microtubules
as a homodimer [16], and thus the 75 kD protein is
presumably the homodimer. The mRNA expression of
MAP4K4 was increased in the primary tumours, con-
sistent with the array result; however, the protein level
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Table 2. Summary of univariate and multivariate Cox regression analysis of overall survival duration
Univariate Multivariate
Variable HR CI (95%) p HR CI (95%) p
Gender −0.066 −0.507–0.375 0.770
Age 0.012 −0.004–0.028 0.151
DKK1 −0.376 −0.850–0.098 0.120
SDCBP 0.446 −0.013–0.905 0.056
LYN 0.719 0.290–1.148 0.001∗
MAP4K4 0.477 0.048–0.906 0.029∗
Differentiation 0.559 0.251–0.867 0.000∗ 0.317 0.979–1.926 0.066
Dukes’ stage 1.025 1.710–4.538 0.000∗ 0.669 1.172–3.251 0.010∗
MID1 −0.712 −1.145–−0.279 0.001∗ −0.498 0.391–0.945 0.027∗
Five-gene signature 1.183 0.752–1.614 0.000∗ 0.888 1.550–3.812 0.000∗
∗ p < 0.05
was decreased in most of the primary tumours, sug-
gesting post-transcriptional modifications of MAP4K4
in the tumour.
Correlation of gene expression with
clinicopathological characteristics of the CRC
patients
To further investigate the role of LYN , SDCBP ,
MAP4K4 , DKK1 , and MID1 in colorectal tumour
metastasis, we measured the protein levels of these
genes in 181 archived paraffin-embedded CRC sam-
ples using immunohistochemical staining (Figure 6)
and analysed the correlation of the clinicopathological
characteristics of these patients with the expression
of LYN , SDCBP , MAP4K4 , DKK1 , MID1 , and the
five-gene signature. As summarized in Table 1, there
were no significant associations of either individual
expression of LYN , SDCBP , MAP4K4 , DKK1 , and
MID1 , or the expression of the five-gene signature
with age or gender of the patients (p > 0.05). How-
ever, we found that expression of LYN , MAP4K4 ,
MID1 , and the five-gene signature correlated closely
with tumour differentiation and lymph node metastasis
(Table 1). In addition, expression of LYN , MAP4K4 ,
and the five-gene signature was significantly associ-
ated with Dukes’ stage (p < 0.01). Moreover, expres-
sion of LYN and MAP4K4 correlated significantly
with tumour invasion (p < 0.05), although the five-
gene signature did not correlate well with tumour
invasion (p = 0.051).
Survival analysis and log-rank test results
To investigate the prognostic value of MAP4K4 , LYN ,
SDCBP , DKK1 , MID1 , and the five-gene signature
for CRC, we evaluated the association of individual
expression of MAP4K4 , LYN , SDCBP , DKK1 , and
MID1 , and expression of the five-gene signature,
with the survival rate using Kaplan–Meier analysis
with the log-rank test. As shown in Figures 7A–7E,
expression of MAP4K4 , LYN , SDCBP , and MID1
was found to correlate significantly with the overall
survival of patients. Notably, the five-gene signature
also correlated highly with the overall survival of
patients (Figure 7F). Clearly, the correlation of the
five-gene signature with patient survival was much
better than any single gene (see Figures 7A–7F).
To determine whether the expression of the five-
gene signature acts as an independent prognostic
factor for CRC, we performed multivariate survival
analysis of the expression of the five-gene signature
with numerous factors such as gender, age, tumour
differentiation, Dukes’ classification, and individual
expression of the five genes. As shown in Table 2,
Dukes’ classification and the expression of MID1 and
the five-gene signature were independent prognostic
factors for CRC patients, of which the five-gene
signature was the best prognostic factor (p < 0.001).
Discussion
In this study, we isolated SCPs from the SW480
cell line in vitro and assessed their ability to grow
subcutaneously on the flanks of nude mice. Less than
50% of the SCPs (29/59) were capable of forming
visible tumours in vivo and the growth traits of the
SCPs were shown to be significantly different. Two
groups of SCPs that exhibited the capability of either
high or low metastasis were separated by orthotopic
implantation of SCP cells in nude mice. Because the
difference of gene profiling between the high and
the low metastatic SCPs may be clinically relevant,
we performed microarray analyses to excavate the
molecules that drove the metastasis.
We used several approaches to identify the genes
involved in CRC metastasis. First, we screened the
genes expressed differentially between the high and
the low metastatic SCPs. We then cross-compared
the differential genes expressed between SCP51 and
SCP58 with those found between SCP58 and SW480/
EGFP, and obtained the common genes associated
with CRC metastasis. Moreover, we picked the
enriched genes from the common genes by using
the gene-annotation enrichment analysis of DAVID.
Finally, we used Geneclip, text-mining software devel-
oped in our laboratory, to find the genes associated
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Figure 4. 32 candidate genes with metastatic potential were identified by microarray analyses. (A) A workflow of the strategy
for identification of the genes associated with CRC metastasis. (B) Venn diagrams of the common differential genes identified
by cross-comparing the genes expressed differentially between SCP51 and SCP58 cells, or between SCP58 and SW480/EGFP.
(C) Hierarchical cluster diagram of 32 differentially expressed genes in SCP51, SCP58 cells, and SW480/EGFP. (D) Hierarchical
cluster diagram of the 32-gene set based on literature profiling and constructing gene co-occurrence networks using default
indicators of Geneclip. (E) A primary co-occurrence network between the 32-gene set and metastasis, colorectal cancer,
melanoma, and other cancers by the Geneclip analysis
with metastasis. We successfully reduced the number
of candidate genes from 143 to 32. The strategy is
straightforward and without any complex calculations,
and is thus adaptable for use in other studies.
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Figure 5. Expression of LYN, SDCBP, MAP4K4, DKK1, and MID1 in tumours. (A) Expression of the genes at the mRNA level
detected by RT-PCR. (B) Expression of the genes at the protein level detected by western blotting. Paired tissues from different
patients: N, normal tissue; T, colorectal tumour tissue
Of the 32 candidate genes, some have been well
studied in CRC or metastasis, while others are poorly
understood in CRC or metastasis. It has been noted
that CA2 [17], CD24 [18,19], DKK1 [20], DSC2 [21],
HOXB8 [22], LYN [23], SEMA3A [24], THBS1 [25],
and VDR [26] are related with CRC; ARNTL, DKK1,
DSC2, LYN, UPP1, and VDR are involved in the reg-
ulation of adhesion, growth, sensitivity or resistance
to anti-cancer drugs of CRC. In addition, COL6A3
[27], EVI1 [28], and MARCKS [29] are known to
be associated with the progression of breast can-
cer, melanoma or prostate cancer. We selected LYN,
SDCBP, MAP4K4, DKK1, and MID1 for profound
investigations because their roles in CRC metasta-
sis are unclear. However, it is known that DKK1
is involved in embryonic development by inhibition
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Figure 6. Immunohistochemical analysis of MAP4K4, LYN, SDCBP, DKK1, and MID1 on colorectal tumours. Low expression
in some tumour tissues is presented in the panels on the left and high expression in tumour tissues in the panels on the right.
Original magnification: 400×
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Figure 7. Correlations of the expression of LYN, SDCBP, MAP4K4, DKK1, MID1, and the five-gene signature with Kaplan–Meier
overall survival of CRC patients. The log-rank test was used to calculate p values
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of the WNT signalling pathway [30]; DKK1 has
been studied in colon [30,31] and gastric cancers
[32]. LYN is a Src family protein tyrosine kinase
expressed preferentially in haematopoietic cells and
B cells. It was shown that activation of LYN stimu-
lated cell proliferation and inhibited apoptosis. The
expression of LYN has also been reported in solid
tumours including prostate cancer [33], pancreatic can-
cer [34], colon carcinoma [35], and Kaposi’s sarcoma
[36]. LYN induced chemoresistance in colon cancer
cell lines via the PI3-K/PKB-mediated cell survival
pathway [35]. MID1 is a member of the tripartite
motif (TRIM) family. It is involved in the formation
of multi-protein structures, acting as anchor points to
microtubules [37]. SDCBP (also called mda-9, syn-
tenin) contains tandemly repeated PDZ domains that
bind the cytoplasmic C-terminal domains of a variety
of transmembrane proteins, which affect cytoskeletal-
membrane organization, cell adhesion, protein traffick-
ing, and activation of transcription factors. SDCBP
was up-regulated in metastatic melanomas [38,39] and
breast and gastric carcinomas [40]. Recently, SDCBP
was shown to be an essential gene in the control of
melanoma progression and metastasis [39]. MAP4K4
is a member of the serine/threonine protein kinase
family. It is known that MAP4K4 specifically acti-
vates MAPK8/JNK [41] and is involved in cell migra-
tion and invasion in ovarian cancer [42] and breast
cancer [43].
In this study, we found that LYN and SDCBP were
up-regulated, while DKK1 and MID1 were down-
regulated in colorectal tumours. The expression of
LYN, MAP4K4, and the five-gene signature were
closely associated with metastasis and Dukes’ stage of
CRC. In addition, the expression of MAP4K4, LYN,
SDCBP, MID1, and the five-gene signature correlated
significantly with the overall survival of CRC patients.
Moreover, the expression of MID1 and the five-gene
signature were independent prognostic factors for CRC
patients, of which the five-gene signature was the best
prognostic factor. Our findings provided new insights
into the role of these genes, particularly the five-gene
signature in CRC progression.
As the genes of interest function in various molec-
ular pathways, their promotion of CRC metastasis
would be achieved by means of regulating numerous
signalling pathways. However, the fact that the five-
gene signature correlates more closely with the metas-
tasis and overall survival of CRC patients suggests
that the concerted effects of many genes, the regu-
lation of several pathways, and the cross-interactions
of the pathways would be more important in CRC
metastasis and patient survival. It has been reported
that the combination of some genes in the metastasis
signature led to a more aggressive metastatic activ-
ity of the breast cancer cell population [10]. Clearly,
how the five-gene signature regulates the metastasis of
CRC needs to be further investigated. siRNA-mediated
knockdown in highly metastatic CRC cell lines and
virus-mediated knock-in in poorly metastatic CRC cell
lines of individual genes and the gene combination will
be our future work. Further investigations with addi-
tional patient cohorts and delineation of the specific
roles of these genes in the metastatic process may lead
to a better understanding of the metastatic mechanisms
and the development of a novel therapeutic strategy.
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Supplemental experimental procedures.
Table S1. Tumour growth under subcutaneous tissue of nude mice of SCPs including SCP3, SCP9, SCP10,
SCP20, SCP28, SCP51, SCP58, and SW480/EGFP (mean ± SD, n = 3).
Table S2. Cell cycles of SCP51, SCP58, and their parent SW480/EGFP cells detected by flow cytometry
(mean ± SD, n = 3).
Table S3. The differential genes between SCP51 and SCP58 cells (SCP51 versus SCP58).
Table S4. The differential genes between SW480/EGFP and SCP58 (SW480/EGFP versus SCP58).
Table S5. Common genes found as the candidates for CRC metastasis when cross-comparing differential
genes expressed between SCP51 and SCP58 cells with the differential genes found between SCP58 and
SW480/EGFP.
Table S6. Genes found in the top ten clusters using gene-annotation enrichment analysis of DAVID.
Table S7. Fold changes in the genes of the top ten clusters using gene-annotation enrichment analysis of
DAVID in SCP51, SCP58 and SW480/EGFP cells.
Table S8. A 32-gene set associated with metastasis of CRC using cross-comparing, functional analysis
and gene annotation, text mining.
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